SCHEMBL6690917

SCHEMBL6690917

O=C(O)c1oc(Br)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
TTR P02766 1/20 0.38
GPR35 Q9HC97 7/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
TSHR P16473 1/20 0.34
PIM1 P11309 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
PTPN6 P29350 1/20 0.32
LCK P06239 1/20 0.32
FYN P06241 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8978501 0.79 GPR35 (0.44) CYP1A2GPR35MEN1KMT2AAKR1C4
SCHEMBL4367459 0.77 KMT2A (0.55) CYP1A2GPR35ALDH1A1HPGDMEN1
SCHEMBL5786219 0.74 TDP1 (0.38) CYP1A2GPR35ALDH1A1HPGDMEN1
SCHEMBL3977197 0.71 AKR1C3 (0.45) GPR35ALDH1A1HPGDAKR1C4AKR1C3
SCHEMBL3972401 0.64 TTR (0.52) TTRGPR35ALDH1A1HPGDMEN1
SCHEMBL1244129 0.63 DAO (0.51) CYP1A2GPR35ALDH1A1HPGDMEN1
SCHEMBL1901529 0.62
SCHEMBL3744691 0.62 CYP1A2 (0.33) CYP1A2TTRALDH1A1HPGDAKR1C4
SCHEMBL1254887 0.62
SCHEMBL274316 0.62 CHRNA4 (0.49) CYP1A2TTRGPR35HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167204-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets FERNANDEZ-POL JOSE A (US) 2004-08-26 US claimed
US-20030225155-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) 2003-12-04 US claimed
US-10188910-B2 Golf ball SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2019-01-29 US disclosed
US-20180126226-A1 GOLF BALL DUNLOP SPORTS CO. LTD. (JP) 2018-05-10 US disclosed
US-20180056137-A1 GOLF BALL DUNLOP SPORTS CO. LTD. (JP) 2018-03-01 US disclosed
US-9533195-B2 Golf ball DUNLOP SPORTS CO. LTD. (JP) 2017-01-03 US disclosed
US-20160144241-A1 GOLF BALL DUNLOP SPORTS CO. LTD. (JP) 2016-05-26 US disclosed
US-9283439-B2 Golf ball DUNLOP SPORTS CO., LTD. (JP) 2016-03-15 US disclosed
US-20140206476-A1 GOLF BALL DUNLOP SPORTS CO. LTD. (JP) 2014-07-24 US disclosed
US-6803379-B2 TREATMENT OF VIRAL, BACTERIAL, PARASITIC, PROLIFERATIVE DISEASES, NEURODEGENERATIVE DISEASES, INFLAMMATORY DISEASES, HEAVY METAL POISONING AND IMMUNOGICAL DISEASES WITH THIOPHENE-2-CARBOXYLIC ACID, 2-FUROIC ACID OR DERIVATIVES POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) 2004-10-12 US disclosed
US-20040167204-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets FERNANDEZ-POL JOSE A (US) 2004-08-26 US disclosed
US-20030225155-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167204-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets ZFX, ZFR, SLC30A6 CYP1A2 1303/4885TTR 33/4885GPR35 3566/4885
US-20030225155-A1 Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets ZFX, ZFR, SLC30A6 CYP1A2 1279/4885TTR 59/4885GPR35 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.